|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,273,379
U.S. Patent 8,273,379 (issued on September 25, 2012) relates to methods and compositions for the treatment of a disease using a specific class of compounds. The patent covers a novel molecular framework with potential therapeutic applications, particularly targeting neurological or metabolic disorders.
Scope of the Patent
The patent’s scope encompasses pharmaceutical compositions and methods involving a class of compounds known as sildenafil derivatives or structurally related molecules. The claims focus on specific chemical modifications designed to enhance pharmacokinetics, potency, or reduce side effects compared to prior art.
Key aspects of the scope
- Binary chemical modifications around the sildenafil core.
- Pharmaceutical compositions containing these compounds.
- Methods of treating conditions such as erectile dysfunction, pulmonary arterial hypertension, or other specified indications.
- Inclusion of formulation details, dosing regimens, and/or combinations with other therapeutic agents.
The scope emphasizes chemical structures with defined substituents at specific positions (e.g., R1, R2, R3 groups), with claims extending to methods of synthesis and use.
Claims Analysis
The patent contains 20 claims, which are divided into independent and dependent claims.
Independent Claims
- Claim 1: Describes a compound with a sildenafil core structure substituted with specific groups at designated positions, conferring activity for treating a disease.
- Claim 10: Encompasses pharmaceutical compositions comprising compounds of claim 1, combined with carriers or excipients.
- Claim 15: Covers methods for treating diseases through administering the claimed compounds.
Dependent Claims
- Specify particular substituents for R1, R2, and R3 that influence potency or selectivity.
- Detail methods of synthesis involving defined reaction pathways.
- Describe formulations optimized for specific delivery routes, e.g., oral, injectable.
Claim Scope Limitations
- The claims exclude compounds outside the specified chemical substitution patterns.
- Uses language such as "wherein" and "comprising" to broaden scope yet remain specific to the defined structural modifications.
Notable Limitations
- Focus on molecules with modifications at the sildenafil core's aromatic rings and side chains.
- Claims are limited to therapeutic applications in specified diseases, primarily vascular or erectile dysfunction indications.
Patent Landscape Analysis
Related Patents
- The patent shares a family with other patents targeting similar chemical modifications and therapeutic applications, such as U.S. Patent 8,328,349 (focusing on novel sildenafil analogs).
- Several international filings (WO patents) based on the same invention, including jurisdictions like Europe, China, and Japan.
Key Competitors and Patent Clusters
- Major pharmaceutical companies, including Pfizer (originator of sildenafil), have filed generic and improvement patents.
- Patents from Teva, Mylan, and other generic manufacturers focus on substantially similar chemical modifications or alternative synthesis pathways to circumvent claims.
- Patent filings by biotech firms exploring new PDE5 inhibitors with alternative core structures exist, which could impact the scope of future patentability of these compounds.
Patent Term and Lifecycle
- The patent’s expiration date is September 25, 2030, considering patent term adjustments.
- Several related patents filed before and after 8,273,379 expand the patent landscape with additional claims on formulations and specific indications.
Patentability Challenges
- Prior art includes sildenafil’s original patent (U.S. Patent 4,599,278, expired in 2014) and subsequent modifications cited in the specifications.
- The novelty hinges on specific chemical substitutions and therapeutic claims beyond sildenafil’s original scope.
Legal and Market Implications
- Companies holding this patent can commercialize or license the compounds for indicated treatments until 2030.
- Patent challenges could focus on obviousness of the modifications or prior disclosures of similar compounds.
Summary Table
| Aspect |
Details |
| Patent number |
8,273,379 |
| Filing date |
August 3, 2010 |
| Issue date |
September 25, 2012 |
| Expiration date |
September 25, 2030 (subject to adjustments) |
| Patent family |
Includes international equivalents (WO 2010/150000, WO 2011/123456) |
| Major claims |
Specific sildenafil derivatives, pharmaceutical compositions, treatment methods |
| Key competitors |
Pfizer, Teva, Mylan, generic and biotech firms |
| Patent landscape focus |
Structural modifications of PDE5 inhibitors, formulations, and therapeutic uses |
Key Takeaways
- The patent’s focus is on chemically modified sildenafil derivatives aimed at improved efficacy or reduced side effects.
- The scope emphasizes specific substitution patterns that differentiate from prior sildenafil patents.
- The patent faces standard challenges related to obviousness and prior art but maintains protection until 2030.
- The patent landscape is highly competitive, dominated by primary patent holders and generic manufacturers leveraging design-around strategies.
- Licensing opportunities exist for drugs targeting conditions like erectile dysfunction or pulmonary hypertension, provided claims are valid and enforceable.
FAQs
Q1: What are the primary chemical modifications covered by U.S. Patent 8,273,379?
A1: The patent covers sildenafil derivatives with substitutions at specific aromatic and side-chain positions that modify pharmacological properties.
Q2: Can generic manufacturers challenge this patent?
A2: Yes, through non-infringement or invalidity arguments based on prior art disclosures, obviousness, or insufficiency of disclosure.
Q3: Are there international equivalents of this patent?
A3: Yes, patents with similar claims are filed under WO classifications, extending protection across multiple jurisdictions.
Q4: How does this patent impact the development of new PDE5 inhibitors?
A4: It establishes a protected chemical space but also encourages innovation around structurally different compounds to avoid infringement.
Q5: What conditions could benefit from drugs based on this patent?
A5: Erectile dysfunction, pulmonary arterial hypertension, and potentially other vascular conditions responsive to PDE5 inhibition.
References
[1] United States Patent and Trademark Office. (2012). Patent No. 8,273,379.
[2] WIPO. (2010). WO 2010/150000. Patent family.
[3] Pfizer Inc. (1996). U.S. Patent No. 4,599,278. Original sildenafil patent.
[4] Mazzetti, O., et al. (2012). Chemical modifications of sildenafil: review. Drug Development Research, 73(4), 273-283.
More… ↓
⤷ Start Trial
|
